Skip to main content
SpringerLink
Log in

Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma.

Methods

We evaluated DA withdrawal in 67 patients with prolactinoma (50 female/17 male) who received DA treatment for at least 2 years and showed normalization of prolactin (PRL) levels and tumor disappearance or ≥50 % tumor shrinkage, retrospectively. Accordingly, patients were divided into two groups as remission and recurrence groups, and factors that predict recurrence were evaluated.

Results

The overall remission rate was 46 %; the remission ratios were 65 % in microprolactinomas and 36 % in macroprolactinomas. Remission rates were 39 % in the bromocriptine withdrawal group and 55 % in the cabergoline withdrawal group. The maximum tumor diameter and baseline PRL levels were significantly higher in the recurrence group (p = 0.001 and p = 0.003, respectively). The mean duration of DA therapy was significantly longer in the remission group (88.7 ± 48.1 and 66.7 ± 30.4 months, respectively, p = 0.026).The mean time to recurrence was 5.3 ± 3.2 months. The mean PRL levels at recurrence time were significantly lower than baseline PRL levels (p = 0.001).

Conclusion

The most important predictors of recurrence were maximum tumor diameter and baseline PRL levels in this study. The remission rate in our study group was higher, which was thought to be associated with the longer duration of DA treatment and that our patients were selected according to certain criteria. Despite these positive results, close monitoring is necessary for detection of early and late recurrence, especially within the first year after DA withdrawal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3–6

    Article  PubMed  Google Scholar 

  2. Colao A, Lombardi G (1998) Growth hormone and prolactine excess. Lancet 352:1455–1461

    Article  CAS  PubMed  Google Scholar 

  3. Colao A, Di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787–800

    Article  CAS  PubMed  Google Scholar 

  4. Zarate A, Canales ES, Cano C, Pilonieta CJ (1983) Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Act Endocrinol 104:139–142

    CAS  Google Scholar 

  5. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high definition computerised tomography. Lancet 2:187–192

    Article  CAS  PubMed  Google Scholar 

  6. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764–772

    Article  CAS  PubMed  Google Scholar 

  7. Wang C, Lam KS, Ma JT, Chan T, Liu MY, Yeung RT (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27:363–371

    Article  CAS  Google Scholar 

  8. Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578–3582

    Article  CAS  PubMed  Google Scholar 

  9. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26–31

    Article  CAS  Google Scholar 

  10. Van’t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175–178

    Article  Google Scholar 

  11. Winkelmann W, Allolio B, Deuss U, Heesen D, Kaulen D (1985) Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In: Macleod RM, Thorner MO, Scapagnini U (eds) Basic and clinical correlates. Liviana Press, Padova, pp 817–822

    Google Scholar 

  12. Rasmussen C, Bergh T, Wide L (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 48:550–554

    CAS  PubMed  Google Scholar 

  13. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659

    Article  CAS  PubMed  Google Scholar 

  14. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 126:489–494

    CAS  PubMed  Google Scholar 

  15. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53–60

    Article  Google Scholar 

  16. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537–546

    Article  CAS  PubMed  Google Scholar 

  17. Cannavo` S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22:354–359

    Article  CAS  PubMed  Google Scholar 

  18. Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G (1994) A cross-over study with the two novel dopaminergic drugs, cabergoline and quinagolide, in hyperprolactinemic patients. J Endocrinol Invest 17:51–57

    Article  CAS  PubMed  Google Scholar 

  19. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Eng J Med 349:2023–2033

    Article  CAS  Google Scholar 

  20. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67(3):426–433

    Article  CAS  Google Scholar 

  21. Hardy J, Vezina JL (1976) Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 15:261–274

    CAS  PubMed  Google Scholar 

  22. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273

    Article  Google Scholar 

  23. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:273–288

    Article  CAS  PubMed  Google Scholar 

  24. Hu J, Zheng X, Zhang W, Yang H (2015) Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18(5):745–751

    Article  CAS  PubMed  Google Scholar 

  25. Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf) 75(6):819–824

    Article  CAS  Google Scholar 

  26. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428–2436

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72(4):507–511

    Article  CAS  Google Scholar 

  28. Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M (2012) Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15(1):25–29

    Article  PubMed  Google Scholar 

  29. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51

    Article  CAS  PubMed  Google Scholar 

  30. Vilar L, Albuquerque JL, Gadelha PS, Rangel Filho F, Siqueira AM, da Fonseca MM, Viana KF, Gomes BS, Lyra R (2015) Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front Endocrinol (Lausanne) 6:11

    Google Scholar 

  31. Kwancharoen R, Auriemma RS, Yenokyan G, Wand GS, Colao A, Salvatori R (2014) Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17(5):451–456

    Article  CAS  PubMed  Google Scholar 

  32. Martín de Santa-Olalla y Llanes M, Andía Melero VM, Jara Albarrán A (2013) Long-term evolution and outcomes of microprolactinoma with medical treatment. Endocrinol Nutr 60(9):489–494

  33. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470

    Article  CAS  PubMed  Google Scholar 

  34. Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179–1183

    Article  CAS  PubMed  Google Scholar 

  35. Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183

    Article  CAS  PubMed  Google Scholar 

  36. Wang F, Gao H, Li C, Bai J, Lu R, Cao L, Wu Y, Hong L, Wu Y, Lan X, Zhang Y (2014) Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. J Neurooncol 116(1):83–88

    Article  CAS  PubMed  Google Scholar 

  37. Yarman S, Ogret YD, Oguz FS (2015) Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas? Genet Test Mol Biomark 19(7):394–398

    Article  CAS  Google Scholar 

  38. Popescu MN, Ionescu E, Iovanescu LC, Cotoi BV, Popescu AI, Ganescu AE, Glodeanu A, Geormaneanu C, Moraru A, Patrascu A (2013) Clinical aggression of prolactinomas: correlations with invasion and recurrence. Rom J Morphol Embryol 54(4):1075–1080

    PubMed  Google Scholar 

  39. Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28:143–169

    Article  CAS  PubMed  Google Scholar 

  40. Orrego JJ, Chandler WF, Barkan AL (2003) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3:189–192

    Article  Google Scholar 

  41. Bassetti M, Spada A, Pezzo G, Giannattasio G (1984) Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 58:268–273

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Capa, 34090, Istanbul, Turkey

    Sema Ciftci Dogansen, Ozlem Soyluk Selcukbiricik, Seher Tanrikulu & Sema Yarman

Authors
  1. Sema Ciftci Dogansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozlem Soyluk Selcukbiricik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seher Tanrikulu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sema Yarman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sema Ciftci Dogansen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dogansen, S.C., Selcukbiricik, O.S., Tanrikulu, S. et al. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?. Pituitary 19, 303–310 (2016). https://doi.org/10.1007/s11102-016-0708-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-016-0708-3

Keywords

Search

Navigation